Figure 1.

¹¹¹In-octreoscan whole body scans prior to somatostatin analogue therapy. (A) Anterior projection, showing uptake in the left malar aspect (small arrow) pre-treatment (July, 2009); (B) posterior projection, showing uptake in the thoracic regions (large arrow) pre-treatment (July, 2009). (C) Anterior and (D) posterior projections of whole body scans at 24 h following the first round of ¹⁷⁷Lu-DOTA-TATE therapy (January, 2010). Abnormal uptake was observed in the left malar region (short continuous arrow), lower thoracic segment (large continuous arrow), liver (short dashed arrow) and in the left distal femur (large dashed arrow). ¹¹¹In, indium-111; ¹⁷⁷Lu, lutetium-177.